Agilon Health (NYSE:AGL) Reaches New 52-Week High Following Analyst Upgrade

Agilon Health, Inc. (NYSE:AGL)’s share price hit a new 52-week high during mid-day trading on Wednesday after Barclays upgraded the stock from an underweight rating to an equal weight rating. Barclays now has a $81.00 price target on the stock. Agilon Health traded as high as $91.85 and last traded at $90.87, with a volume of 241283 shares traded. The stock had previously closed at $85.27.

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company restated an “overweight” rating and issued a $72.00 target price (up from $37.50) on shares of Agilon Health in a research note on Friday, May 8th. Wall Street Zen upgraded Agilon Health from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Citigroup reissued a “neutral” rating and issued a $80.00 price objective (up from $18.75) on shares of Agilon Health in a research report on Friday, May 15th. Jefferies Financial Group raised Agilon Health from a “hold” rating to a “buy” rating and upped their target price for the company from $27.50 to $48.00 in a research report on Thursday, May 7th. Finally, TD Cowen reiterated a “hold” rating and issued a $55.00 price target (up from $17.00) on shares of Agilon Health in a research note on Monday, May 11th. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Agilon Health currently has a consensus rating of “Hold” and a consensus price target of $58.73.

Institutional Investors Weigh In On Agilon Health

Large investors have recently made changes to their positions in the stock. Wealthcare Advisory Partners LLC purchased a new position in Agilon Health in the 3rd quarter worth $26,000. CIBC Bancorp USA Inc. acquired a new position in shares of Agilon Health in the third quarter valued at about $34,000. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Agilon Health in the third quarter worth about $37,000. Tower Research Capital LLC TRC raised its stake in shares of Agilon Health by 214.0% in the second quarter. Tower Research Capital LLC TRC now owns 37,079 shares of the company’s stock worth $85,000 after purchasing an additional 25,270 shares during the last quarter. Finally, Independent Advisor Alliance acquired a new stake in shares of Agilon Health during the third quarter worth about $39,000.

Agilon Health Price Performance

The stock has a fifty day moving average of $35.01 and a 200 day moving average of $23.33. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -4.21 and a beta of 2.29. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.04 and a quick ratio of 1.04.

Agilon Health (NYSE:AGL) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.76. Agilon Health had a negative net margin of 6.09% and a negative return on equity of 146.03%. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.38 billion. On average, analysts expect that Agilon Health, Inc. will post -3.75 EPS for the current fiscal year.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.